| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Puberty | 7 | 2024 | 104 | 2.730 |
Why?
|
| Neuroblastoma | 9 | 2020 | 550 | 2.670 |
Why?
|
| Adrenarche | 8 | 2019 | 11 | 2.640 |
Why?
|
| Brain | 19 | 2025 | 3225 | 2.240 |
Why?
|
| Dehydroepiandrosterone | 9 | 2020 | 33 | 2.130 |
Why?
|
| Mental Health | 7 | 2025 | 378 | 1.980 |
Why?
|
| Amygdala | 4 | 2019 | 87 | 1.830 |
Why?
|
| Cerebral Cortex | 6 | 2020 | 481 | 1.590 |
Why?
|
| Maternal Behavior | 3 | 2023 | 71 | 1.490 |
Why?
|
| Parenting | 5 | 2024 | 349 | 1.370 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2022 | 52 | 1.320 |
Why?
|
| Adolescent Development | 8 | 2024 | 33 | 1.300 |
Why?
|
| Induction Chemotherapy | 3 | 2020 | 57 | 1.240 |
Why?
|
| Sarcoma | 2 | 2022 | 209 | 1.240 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2022 | 128 | 1.230 |
Why?
|
| Depression | 8 | 2025 | 1366 | 1.160 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2025 | 3869 | 1.100 |
Why?
|
| Child | 44 | 2025 | 25869 | 1.060 |
Why?
|
| Bacterial Infections | 2 | 2020 | 329 | 0.980 |
Why?
|
| Saliva | 8 | 2024 | 132 | 0.950 |
Why?
|
| Emotions | 4 | 2023 | 366 | 0.920 |
Why?
|
| Adolescent | 36 | 2025 | 20574 | 0.910 |
Why?
|
| Adolescent Behavior | 2 | 2025 | 173 | 0.910 |
Why?
|
| White Matter | 4 | 2020 | 212 | 0.900 |
Why?
|
| Bone Neoplasms | 3 | 2025 | 447 | 0.840 |
Why?
|
| Anxiety | 5 | 2025 | 1006 | 0.830 |
Why?
|
| Problem Behavior | 1 | 2023 | 41 | 0.800 |
Why?
|
| Osteosarcoma | 2 | 2024 | 264 | 0.770 |
Why?
|
| Female | 53 | 2025 | 71507 | 0.760 |
Why?
|
| Pituitary Gland | 4 | 2019 | 89 | 0.760 |
Why?
|
| Longitudinal Studies | 13 | 2025 | 1513 | 0.730 |
Why?
|
| Liposarcoma | 1 | 2021 | 25 | 0.720 |
Why?
|
| Humans | 70 | 2025 | 133383 | 0.710 |
Why?
|
| Child Abuse | 3 | 2023 | 203 | 0.710 |
Why?
|
| Psychotic Disorders | 5 | 2023 | 149 | 0.700 |
Why?
|
| Testosterone Congeners | 1 | 2020 | 19 | 0.680 |
Why?
|
| Male | 46 | 2025 | 65596 | 0.680 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 26 | 0.670 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 96 | 0.650 |
Why?
|
| Neutropenia | 2 | 2024 | 205 | 0.640 |
Why?
|
| Depressive Disorder, Major | 2 | 2023 | 472 | 0.640 |
Why?
|
| Sex Characteristics | 6 | 2019 | 335 | 0.640 |
Why?
|
| Rhabdomyosarcoma | 1 | 2022 | 211 | 0.610 |
Why?
|
| Immunotherapy | 3 | 2021 | 750 | 0.600 |
Why?
|
| Mother-Child Relations | 1 | 2019 | 79 | 0.580 |
Why?
|
| Gene-Environment Interaction | 1 | 2019 | 130 | 0.580 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2017 | 2 | 0.570 |
Why?
|
| Mental Disorders | 2 | 2016 | 893 | 0.570 |
Why?
|
| Hydrocortisone | 7 | 2024 | 246 | 0.570 |
Why?
|
| Blood Transfusion | 1 | 2019 | 296 | 0.550 |
Why?
|
| Pituitary-Adrenal System | 5 | 2019 | 44 | 0.550 |
Why?
|
| Hypothalamo-Hypophyseal System | 5 | 2019 | 72 | 0.540 |
Why?
|
| Parahippocampal Gyrus | 1 | 2016 | 2 | 0.530 |
Why?
|
| Testosterone | 7 | 2020 | 622 | 0.520 |
Why?
|
| Mycoses | 1 | 2017 | 117 | 0.510 |
Why?
|
| Medicaid | 1 | 2019 | 254 | 0.510 |
Why?
|
| Parent-Child Relations | 1 | 2018 | 253 | 0.510 |
Why?
|
| Dentate Gyrus | 1 | 2016 | 55 | 0.500 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2016 | 15 | 0.500 |
Why?
|
| Pyridazines | 1 | 2016 | 54 | 0.500 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2016 | 141 | 0.490 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 612 | 0.490 |
Why?
|
| Phobia, Social | 1 | 2015 | 7 | 0.490 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 343 | 0.490 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2016 | 81 | 0.480 |
Why?
|
| Health Care Costs | 1 | 2019 | 409 | 0.480 |
Why?
|
| Child Development | 2 | 2020 | 286 | 0.460 |
Why?
|
| Marijuana Abuse | 4 | 2019 | 53 | 0.460 |
Why?
|
| Imidazoles | 1 | 2016 | 218 | 0.460 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 259 | 0.460 |
Why?
|
| Infant | 11 | 2022 | 13245 | 0.450 |
Why?
|
| Young Adult | 17 | 2025 | 9923 | 0.440 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 225 | 0.440 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 407 | 0.440 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 480 | 0.440 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2020 | 1008 | 0.430 |
Why?
|
| Affect | 1 | 2015 | 172 | 0.420 |
Why?
|
| Prefrontal Cortex | 4 | 2023 | 218 | 0.420 |
Why?
|
| Length of Stay | 1 | 2019 | 1394 | 0.400 |
Why?
|
| Neural Pathways | 3 | 2019 | 283 | 0.390 |
Why?
|
| Cell Movement | 1 | 2016 | 906 | 0.390 |
Why?
|
| Punishment | 2 | 2023 | 9 | 0.350 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1313 | 0.350 |
Why?
|
| Nephroma, Mesoblastic | 1 | 2010 | 10 | 0.340 |
Why?
|
| Neoplasms | 4 | 2022 | 2992 | 0.340 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 69 | 0.340 |
Why?
|
| Frontal Lobe | 3 | 2022 | 121 | 0.330 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 24 | 0.320 |
Why?
|
| Child, Preschool | 10 | 2024 | 14874 | 0.310 |
Why?
|
| Adult | 17 | 2024 | 31686 | 0.310 |
Why?
|
| Facial Expression | 2 | 2019 | 28 | 0.300 |
Why?
|
| Adrenal Glands | 2 | 2019 | 54 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1353 | 0.270 |
Why?
|
| Prognosis | 3 | 2022 | 5044 | 0.270 |
Why?
|
| Anxiety Disorders | 3 | 2024 | 736 | 0.270 |
Why?
|
| Sex Factors | 3 | 2025 | 1353 | 0.250 |
Why?
|
| Connectome | 2 | 2018 | 120 | 0.250 |
Why?
|
| Hair | 2 | 2015 | 29 | 0.240 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3740 | 0.240 |
Why?
|
| Temperament | 1 | 2025 | 32 | 0.240 |
Why?
|
| Ifosfamide | 1 | 2024 | 35 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3363 | 0.230 |
Why?
|
| Etoposide | 1 | 2024 | 120 | 0.220 |
Why?
|
| Residence Characteristics | 2 | 2025 | 290 | 0.220 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1310 | 0.220 |
Why?
|
| Phenylurea Compounds | 1 | 2024 | 56 | 0.220 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 108 | 0.220 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2024 | 103 | 0.220 |
Why?
|
| Sarcoma, Ewing | 1 | 2025 | 116 | 0.220 |
Why?
|
| Video Games | 1 | 2025 | 98 | 0.220 |
Why?
|
| Quinolines | 1 | 2024 | 115 | 0.210 |
Why?
|
| Fathers | 1 | 2024 | 72 | 0.210 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2023 | 16 | 0.210 |
Why?
|
| Survival Rate | 2 | 2020 | 2207 | 0.210 |
Why?
|
| Hippocampus | 2 | 2019 | 861 | 0.210 |
Why?
|
| Psychopathology | 1 | 2023 | 34 | 0.200 |
Why?
|
| Fear | 1 | 2024 | 205 | 0.200 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8633 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 5443 | 0.200 |
Why?
|
| Phenylketonurias | 1 | 2022 | 14 | 0.190 |
Why?
|
| Social Environment | 1 | 2023 | 124 | 0.190 |
Why?
|
| Translocation, Genetic | 2 | 2017 | 363 | 0.190 |
Why?
|
| Stress, Psychological | 2 | 2019 | 604 | 0.190 |
Why?
|
| Transplantation Conditioning | 2 | 2020 | 300 | 0.180 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 158 | 0.180 |
Why?
|
| Genotype | 2 | 2019 | 2720 | 0.180 |
Why?
|
| Gray Matter | 2 | 2018 | 44 | 0.170 |
Why?
|
| Educational Status | 1 | 2022 | 294 | 0.170 |
Why?
|
| Leukemia | 1 | 2024 | 374 | 0.170 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1693 | 0.170 |
Why?
|
| Brain Mapping | 1 | 2023 | 405 | 0.170 |
Why?
|
| Lymphoma | 1 | 2024 | 331 | 0.170 |
Why?
|
| Organ Size | 3 | 2018 | 464 | 0.170 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 35 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 1156 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 69 | 0.170 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 330 | 0.170 |
Why?
|
| Corpus Callosum | 1 | 2020 | 104 | 0.160 |
Why?
|
| Dactinomycin | 1 | 2019 | 66 | 0.160 |
Why?
|
| Foot Diseases | 1 | 2019 | 23 | 0.160 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 38 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 154 | 0.160 |
Why?
|
| Thigh | 1 | 2019 | 52 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2020 | 186 | 0.150 |
Why?
|
| Thoracic Wall | 1 | 2019 | 40 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 294 | 0.150 |
Why?
|
| Extremities | 1 | 2019 | 87 | 0.150 |
Why?
|
| Remission Induction | 1 | 2019 | 307 | 0.150 |
Why?
|
| Vincristine | 1 | 2019 | 196 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 211 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 624 | 0.140 |
Why?
|
| Theory of Mind | 1 | 2018 | 28 | 0.140 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2021 | 222 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 401 | 0.140 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 12 | 0.140 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2019 | 207 | 0.140 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2017 | 65 | 0.140 |
Why?
|
| Marijuana Use | 1 | 2017 | 13 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2024 | 17567 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 236 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 151 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 426 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 899 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2022 | 872 | 0.130 |
Why?
|
| Gene Amplification | 1 | 2017 | 245 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 142 | 0.130 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 255 | 0.130 |
Why?
|
| Sexual Maturation | 1 | 2016 | 49 | 0.130 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 103 | 0.130 |
Why?
|
| Androgens | 1 | 2019 | 300 | 0.130 |
Why?
|
| Wilms Tumor | 1 | 2018 | 119 | 0.130 |
Why?
|
| Fetus | 1 | 2020 | 601 | 0.130 |
Why?
|
| Neural Crest | 1 | 2016 | 56 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 767 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 151 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1469 | 0.120 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 252 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1531 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 82 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 5199 | 0.120 |
Why?
|
| Microbiota | 1 | 2021 | 443 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 237 | 0.120 |
Why?
|
| Puberty, Precocious | 1 | 2015 | 29 | 0.120 |
Why?
|
| Cerebellum | 1 | 2019 | 467 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 1849 | 0.120 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 183 | 0.120 |
Why?
|
| Life Change Events | 1 | 2015 | 65 | 0.120 |
Why?
|
| Sexual Development | 1 | 2015 | 23 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2020 | 6585 | 0.110 |
Why?
|
| Psychological Trauma | 1 | 2015 | 24 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2016 | 780 | 0.110 |
Why?
|
| Immunity | 1 | 2015 | 184 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1097 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2016 | 441 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 494 | 0.110 |
Why?
|
| Infant, Premature | 1 | 2019 | 858 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 351 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2016 | 1136 | 0.100 |
Why?
|
| Physician Executives | 1 | 2013 | 39 | 0.100 |
Why?
|
| Work Schedule Tolerance | 1 | 2013 | 43 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2014 | 232 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 460 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 1013 | 0.100 |
Why?
|
| Risk Factors | 3 | 2017 | 10957 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 822 | 0.100 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2013 | 83 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2020 | 13103 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2014 | 483 | 0.090 |
Why?
|
| Perception | 1 | 2013 | 238 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 713 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2023 | 3719 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2014 | 367 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 571 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 396 | 0.090 |
Why?
|
| Incidence | 2 | 2017 | 3396 | 0.090 |
Why?
|
| Fibrosarcoma | 1 | 2010 | 26 | 0.080 |
Why?
|
| Neuroimaging | 3 | 2020 | 376 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2014 | 578 | 0.080 |
Why?
|
| Apoptosis | 1 | 2016 | 1928 | 0.080 |
Why?
|
| Datasets as Topic | 2 | 2021 | 105 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2015 | 1713 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2559 | 0.080 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2008 | 10 | 0.070 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 651 | 0.070 |
Why?
|
| Pediatrics | 2 | 2018 | 1221 | 0.070 |
Why?
|
| Phenotype | 1 | 2017 | 4577 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1411 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 7602 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2855 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 782 | 0.060 |
Why?
|
| Parks, Recreational | 1 | 2025 | 4 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 616 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 1191 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2025 | 83 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 2205 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2018 | 809 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1973 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 125 | 0.050 |
Why?
|
| United States | 1 | 2019 | 11726 | 0.050 |
Why?
|
| Australia | 1 | 2023 | 191 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 237 | 0.050 |
Why?
|
| Psychology, Adolescent | 1 | 2021 | 35 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2023 | 253 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 356 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 288 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2020 | 118 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2023 | 253 | 0.040 |
Why?
|
| Health Promotion | 1 | 2023 | 404 | 0.040 |
Why?
|
| Caudate Nucleus | 1 | 2019 | 37 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 404 | 0.040 |
Why?
|
| Mice | 1 | 2016 | 18936 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2018 | 22 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 725 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 28987 | 0.040 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2018 | 38 | 0.040 |
Why?
|
| Functional Neuroimaging | 1 | 2018 | 35 | 0.040 |
Why?
|
| Social Perception | 1 | 2018 | 56 | 0.040 |
Why?
|
| Methamphetamine | 1 | 2018 | 48 | 0.040 |
Why?
|
| Animals | 2 | 2016 | 36223 | 0.040 |
Why?
|
| Tobacco Use Disorder | 1 | 2018 | 88 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2017 | 140 | 0.030 |
Why?
|
| Intelligence | 1 | 2017 | 107 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 345 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 719 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 376 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2017 | 196 | 0.030 |
Why?
|
| Social Behavior | 1 | 2018 | 230 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 128 | 0.030 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 204 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 837 | 0.030 |
Why?
|
| Alcoholism | 1 | 2018 | 252 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1073 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 3044 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2017 | 333 | 0.030 |
Why?
|
| Cognition | 1 | 2021 | 818 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1770 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 215 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2014 | 29 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 992 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1204 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1340 | 0.030 |
Why?
|
| Child Behavior | 1 | 2015 | 235 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 470 | 0.020 |
Why?
|
| Wakefulness | 1 | 2013 | 104 | 0.020 |
Why?
|
| Workload | 1 | 2013 | 150 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 855 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3418 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3106 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2008 | 49 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 568 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2956 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 153 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 446 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21502 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2013 | 1253 | 0.010 |
Why?
|